These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration. von Achenbach C; Hevia Hernandez G; von Gunten S Pharmacology; 2022; 107(11-12):556-563. PubMed ID: 36349790 [TBL] [Abstract][Full Text] [Related]
26. [The use of immunoglobulins in the treatment of infectious diseases]. Szenborn L Pol Merkur Lekarski; 2011 Jun; 30(180):441-7. PubMed ID: 21751556 [TBL] [Abstract][Full Text] [Related]
27. [Use of intravenous immunoglobulin preparations (IVIG) in treatment of primary cell immunodeficiencies]. Siwińska-Gołebiowska H; Czerwińska-Kartowicz I; Markiewicz K Postepy Hig Med Dosw; 2002; 56 Suppl():33-40. PubMed ID: 12661412 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN; J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003 [TBL] [Abstract][Full Text] [Related]
30. Intravenous immunoglobulin treatment of immunodeficiency disorders. Schwartz SA Pediatr Clin North Am; 2000 Dec; 47(6):1355-69. PubMed ID: 11131000 [TBL] [Abstract][Full Text] [Related]
31. [Use of intravenous and subcutaneous human immunoglobulins]. Ramus B; Benbrahim O; Chérin P Soins; 2019 Mar; 64(833):13-18. PubMed ID: 30879622 [TBL] [Abstract][Full Text] [Related]
32. Recommended indications for the administration of polyclonal immunoglobulin preparations. Delforge M; Farber CM; Spath P; Kaveri S; Witte T; Misbah SA; Hübner R; Haerynck F; Latinne D; Muylle L; Toungouz M; Deneys V; Acta Clin Belg; 2011; 66(5):346-60. PubMed ID: 22145269 [TBL] [Abstract][Full Text] [Related]
33. Immune biological products: normal and specific immunoglobulin. Fara GM; Di Roma S Ann Ig; 1994; 6(1):3-12. PubMed ID: 7530971 [No Abstract] [Full Text] [Related]
34. [Colombian Guidelines of clinical practice for the use of immunoglobulins in the treatment of replacement and immunomodulation]. Olivares MM; Olmos CE; Álvarez MI; Fajardo AM; Zea-Vera AF; Ortega MC; Medina D; Pérez PM; Beltrán DG; Duque B; Álvarez CA; Lenis G; Solano JM; Gómez D; Franco JL; Díaz MC; Orrego JC; Velásquez MM; Chaparro M; Pinto JL; Izquierdo Á; Ramírez SF Rev Alerg Mex; 2017; 64 Suppl 2():s5-s65. PubMed ID: 28863425 [TBL] [Abstract][Full Text] [Related]
36. [Immunoglobulins: multiple potential therapeutic proteins for use in immune deficits]. Adoue D; Grivel T Rev Med Interne; 2010 Dec; 31(9 Suppl):H9-11. PubMed ID: 20965374 [No Abstract] [Full Text] [Related]
37. [Clinical use of human immunoglobulins]. Kondi V; Mitrică N Microbiol Parazitol Epidemiol (Bucur); 1969; 14(3):201-9. PubMed ID: 4186519 [No Abstract] [Full Text] [Related]
38. Cerebral sinus thrombosis in a patient with humoral immunodeficiency on intravenous immunoglobulin therapy: a case report. Barada W; Muwakkit S; Hourani R; Bitar M; Mikati M Neuropediatrics; 2008 Apr; 39(2):131-3. PubMed ID: 18671192 [TBL] [Abstract][Full Text] [Related]
39. [Immunoglobulins and immune deficiency: methods of administration]. Suarez F Rev Med Interne; 2005 Oct; 26 Spec No 1():25-8. PubMed ID: 16475260 [No Abstract] [Full Text] [Related]